B+
Bull case
25%
Probability
Target price
$13.50
+61.9% vs current
BCRX
BioCrystBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$10.50
+25.9% vs current
B-
Bear case
25%
Probability
Target price
$6.50
-22.1% vs current
AI sentiment snapshot
Latest data as of 2026-04-28
Recent news sentiment (30D)
+57.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+72.1
Score
AI commentary
Primary-source evidence still supports a constructive but cautious monitoring view rather than a strong bullish thesis. BioCryst entered 2026 with maintained ORLADEYO guidance, first-time profitability, pediatric label expansion, and an expanded HAE platform after acquiring Astria, but the next stock-moving proof point is still the May 6, 2026 quarterly update and whether seasonal payer dynamics disrupt the full-year setup. Recent headline flow is light, trusted-news coverage in the packet is sparse, and no robust analyst-revision set was confirmed, so confidence should stay moderate rather than aggressive. [#IR-2026-04-15] [#IR-2026-01-23] [#8-K-2026-02-26] [#10-K-2026-02-26]
RankAlpha Sentiment Codex - 2026-04-28
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06catalystMay 6, 2026 Q1 update is the next execution check on ORLADEYOHigh impact
BioCryst said on April 15, 2026 that it will report first quarter 2026 results on May 6, 2026. That print matters because management maintained 2026 ORLADEYO revenue guidance at $625 million to $645 million after reporting $601.8 million of 2025 ORLADEYO revenue, while also cautioning that first-quarter payor reauthorizations can temporarily move patients from paid drug to free product. [#IR-2026-04-15] [#8-K-2026-02-26] [#10-K-2026-02-26]
2026-12-31eventBCX17725 Phase 1 data by year-end 2026High impact
BioCryst said BCX17725, a KLK5 inhibitor for Netherton syndrome, is enrolling and dosing, with data expected in up to 12 patients by the end of 2026. This is an early-stage but real pipeline catalyst for a company still viewed largely through its HAE franchise. [#8-K-2026-02-26] [#10-K-2026-02-26]
2027-12-31catalystNavenibart Phase 3 execution toward end-2027 filingHigh impact
BioCryst said navenibart is in Phase 3, ALPHA-ORBIT is enrolling, and the program is on track to support a regulatory filing by the end of 2027 following the Astria acquisition completed in January 2026. The asset expands BioCryst beyond ORLADEYO, but the value unlock is long-dated and still subject to trial execution and competitive HAE readouts. [#IR-2026-01-23] [#8-K-2026-02-26] [#10-K-2026-02-26]
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-28 • Updated nightlySource: Internal modelMethodology